# US 2017/0253610 A1 · Nitrogen-containing analogs of salinomycin, synthesis and use against cancer stem cells and malaria

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253610 A1
- Document ID: US20170253610A1
- Status: Published application
- Kind: A1
- Application number: 15/510,427
- Filed: 2015-09-14
- Published: 2017-09-07
- Earliest claimed: 2014-09-12
- Assignees: Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche M edicale (INSERM); Universite Paris Descartes; Uiversite Paris-SUD
- Applicants: Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (INSERM); Universite Paris Descartes; Universtie Paris-SUD
- Inventors: Maryam Mehrpour; Raphael Rodriguez; Antje Hienzsch; Mai Trang; Ahmed Hamai
- Web page: https://patentgrep.com/patent/US20170253610A1

## CPC

- C07D 493/20: Spiro-condensed systems
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/35: having six-membered rings with one oxygen as the only ring hetero atom
- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/664: Amides of phosphorus acids
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 15/14: for lactation disorders, e.g. galactorrhoea
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07H 7/06: Heterocyclic radicals
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention concerns compounds of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diasteroisomers thereof formula (I): wherein at least one of W, X and Y is selected from the group consisting of —NR1R2; —NR3—(CH2)n—NR4R5; —O—(CH2)n—NR4R5; —NR3—(CH2)n—N′R6R7R8; and —O—(CH2)n—N′R6R7R8 and Z is a functional group capable of chelating iron salts. The present invention also concerns the compounds of formula (I) for use as a drug, in particular, in the treatment of cancer and malaria.

## Claims

### Claim 1

A compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diasteroisomers thereof:
wherein:
W is selected from the group consisting of ═O; —NR1R2; —NR3—(CH2)n—NR4R5; —O—(CH2)n—NR4R5; —NR3—(CH2)n—N+R6R7R8 and —O—(CH2)n—N+R6R7R8;
X is selected from the group consisting of ═O, —OH; —NR1R2; —NR3—(CH2)n—NR4R5; —O—(CH2)n—NR4R5; —NR3—(CH2)n—N+R6R7R8 and —O—(CH2)n—N+R6R7R8,
Y is selected from the group consisting of —OH; ═N—OH; —NR1R2, —NR3—(CH2)n—NR4R5; —O—(CH2)n—NR4R5, —NR3—(CH2)n—N+R6R7R8 and —O—(CH2)n—N+R6R7R8,
R1 and R2, identical or different, are selected from the group consisting of H; (C1-C16)-alkyl; (C3-C16)-alkenyl; (C3-C16)-alkynyl; (C3-C16)-cycloalkyl; aryl; heteroaryl; (C1-C6)-alkyl-aryl; (C1-C6)-alkyl-heteroaryl; or R1 represents H and
R2 represents OR9, where R9 is H, (C1-C6)-alkyl, aryl and (C1-C6)-alkyl-aryl;
R3 is selected from the group consisting of H; (C1-C6)-alkyl; (C1-C6)-alkyl-aryl;
R4 and R5, identical or different, are selected from the group consisting of H; (C1-C6)-alkyl; aryl and (C1-C6)-alkyl-aryl;
R6, R7 and R8, identical or different, are selected from the group consisting of (C1-C6)-alkyl; aryl and (C1-C6)-alkyl-aryl;
Z is a group such as OH; NHNR9R10, NHOC(O)R11; N(OH)—C(O)R11; OOH, SR12; 2-aminopyridine; 3-aminopyridine; —NR3—(CH2)n—NR4R5; and —NR3—(CH2)n—OH; where:
R9 and R10, identical or different, are selected from the group consisting of H, (C1-C6)-alkyl, aryl and (C1-C6)-alkyl-aryl;
R11 is selected from the group consisting of H; (C1-C16)-alkyl; (C3-C16)-alkenyl; (C3-C16)-alkynyl; aryl; heteroaryl; (C1-C6)-alkyl-aryl; (C1-C6)-alkyl-heteroaryl;
R12 is selected from the group consisting of H; (C1-C16)-alkyl; (C3-C16)-alkenyl;
(C3-C16)-alkynyl; aryl; heteroaryl; (C1-C6)-alkyl-aryl; (C1-C6)-alkyl-heteroaryl n=0,2,3,4, 5 or6,
with the proviso that at least one of W, X and Y is selected from the group consisting of —NR1R2; —NR3—(CH2)n—NR4R5; —O—(CH2)n—NR4R5; —NR3—(CH2)n—N+R6R7R8 and —O—(CH2)n—N+R6R7R8.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein:
R1 and R2, identical or different, are selected from the group consisting of H; (C1-C16)-alkyl; (C3-C16)-alkenyl; (C3-C16)-alkynyl; (C3-C16)-cycloalkyl; and (C1-C6)-alkyl-heteroaryl,
R3 is selected from the group consisting of H; and (C1-C6)-alkyl;
R4 and R5, identical or different, are selected from the group consisting of H; (C1-C6)-alkyl; and (C1-C6)-alkyl-aryl.

### Claim 3 (depends on 1, 2)

The compound according to claim 1 or 2, wherein R1 is H and R2 is selected from the group consisting of (C1-C16)-alkyl, advantageously (C3-C14)-alkyl; (C3-C16)-alkenyl, advantageously (C3-C5)-alkenyl; (C3-C16)-alkynyl, advantageously (C3-C5)-alkynyl; (C3-C16)-cycloalkyl, advantageously (C3-C6)-cycloalkyl; and (C1-C6)-alkyl-heteroaryl advantageously, CH2-pyridinyl.

### Claim 4 (depends on 1, 2, 3)

The compound of formula (I) according to any of claims 1 to 3, wherein Z is OH or NHOH, advantageously OH.

### Claim 5 (depends on 1, 2, 3, 4)

The compound according to any of claims 1 to 4, wherein W, X and Y, identical or different, are selected from the group consisting of —NR1R2; —NR3—(CH2)n—NR4R5; —O—(CH2)n—NR4R5; —NR3—(CH2)n—N+R6R7R8; and —O—(CH2)n—N+R6R7R8; R1 to R8 and n being as previously defined.

### Claim 6 (depends on 1, 2, 3, 4)

The compound according to any of claims 1 to 4, wherein two of X, Y or Z, identical or different, are selected from the group consisting of —NR1R2; —NR3—(CH2)n—NR4R5; —O—(CH2)n—NR4R5; —NR1—(CH2)n—N+R6R7R8; and —O—(CH2)n—N+R6R7R8; R1 to R8 and n being as previously defined.

### Claim 7 (depends on 1, 2, 3, 4)

The compound of formula (I) according to any of claims 1 to 4, wherein one of X, Y or Z is selected from the group consisting of —NR1R2; —NR3—(CH2)n—NR4R5; —O—(CH2)n—NR4R5; —NR1—(CH2)n—N+R6R7R8; and —O—(CH2)n—N+R6R7R8, R1 to R8 and n being as previously defined.

### Claim 8 (depends on 7)

The compound of formula (I) according to claim 7, wherein X is selected from the group consisting of —NR1R2; —NR3—(CH2)n—NR4R5, —O—(CH2)n—NR4R5; —NR1—(CH2)n—N+R6R7R8; and —O—(CH2)n—N+R6R7R8, advantageously —NR1R2; —NR3—(CH2)n—NR4R5 and —O—(CH2)n—NR4R5 and Y is OH; R1 to R8 and n being as previously defined.

### Claim 9 (depends on 7)

The compound of formula (I) according to claim 7, wherein X is selected from the group consisting of ═O and OH, advantageously OH and Y is selected from the group consisting of —NR1R2; —NR3—(CH2)n—NR4R5; —O—(CH2)n—NR4R5; —NR1—(CH2)n—N+R6R7R8; and —O—(CH2)n—N+R6R7R8, advantageously —NR1R2; —NR3—(CH2)n—NR4R5 and —O—(CH2)n—NR4R5, R1 to R8 and n being as previously defined.

### Claim 10 (depends on 9)

The compound according to claim 9, wherein X is OH, Z is OH and Y is NR1R2 where R1 is H and R2 is selected from the group consisting of (C1-C16)-alkyl, advantageously (C8-C14)-alkyl; (C3-C16)-alkenyl, advantageously (C3-C5)-alkenyl; (C3-C16)-alkynyl, advantageously (C3-C5)-alkynyl and (C3-C16)-cycloalkyl, advantageously (C3-C6)-cycloalkyl.

### Claim 11 (depends on 1)

The compound according to claim 1, selected from the group consisting of:

### Claim 12

The compound according to any of the preceding claims for use as a drug.

### Claim 13 (depends on 12)

The compound for use according to claim 12 in the treatment of cancer, advantageously breast cancer.

### Claim 14 (depends on 12)

The compound for use according to claim 12 in the prevention of cancer relapse and/or metastases.

### Claim 15 (depends on 12)

The compound for use according to claim 12 for the treatment of malaria.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A pharmaceutical composition comprising at least a compound of formula (I) according to any one of claims 1 to 11, a pharmaceutically acceptable salt, solvate or hydrate thereof, and at least one pharmaceutically acceptable excipient, advantageously for use in the treatment of cancer, such as breast cancer.

### Claim 17 (depends on 16)

The pharmaceutical composition according to claim 16, further comprising another anticancer drug, advantageously Adriamycin and Cyclophosphamide or Docetaxel.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

A pharmaceutical product comprising:
a) the compound of formula (I) according to any of claims 1 to 11, and
b) another chemotherapy compound, such as Adriamycin and Cyclophosphamide or Docetaxel,
as combination product for simultaneous, separate or staggered use as a medicament, in particular in the treatment of cancer, advantageously breast cancer.
